← All trials
NCT05032391
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 22, 2019
- Primary completion
- Sep 22, 2019
- Completion date
- Oct 25, 2019
- First posted
- Sep 2, 2021
- Last posted
- Sep 5, 2021
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Limited Liability Company Pharm AidLead sponsor
- Tyumen State Medical AcademyStudy director
- Perm State Medical University named after Academician E.A. WagnerStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.